Processa Pharmaceuticals annual free cash flow
2012
2013
2014
2015
2016
2017
2018
2023
2024
Processa Pharmaceuticals Free Cash Flow (FCF) History (PCSA)
Processa Pharmaceuticals reported −$11.2M in free cash flow for fiscal 2024, a decrease of $3.2M from the previous fiscal year.
View full Processa Pharmaceuticals company overviewProcessa Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$11.2M | −$3.2M | — | — |
| 2023 | 2023-12-31 | −$8.1M | −$4.3M | — | — |
| 2018 | 2018-12-31 | −$3.7M | −$2.1M | — | — |
| 2017 | 2017-12-31 | −$1.7M | $503,573 | — | — |
| 2016 | 2016-12-31 | −$2.2M | −$1.3M | — | −43576.24% |
| 2015 | 2015-12-31 | −$873,305 | $1.8M | — | −769.94% |
| 2014 | 2014-12-31 | −$2.7M | −$136,202 | — | −2520.21% |
| 2013 | 2013-12-31 | −$2.6M | −$339,605 | — | −821.31% |
| 2012 | 2012-12-31 | −$2.2M | — | — | −1158.94% |
Processa Pharmaceuticals quarterly free cash flow
Q3.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.17
Q2.17
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2017 | 2017-06-30 | −$297,230 | −$20,708 | — | — |
| Q1 2017 | 2017-03-31 | −$59,580 | $443,907 | — | — |
| Q4 2015 | 2015-12-31 | −$46,070 | $424,215 | — | — |
| Q3 2015 | 2015-09-30 | −$47,226 | $502,960 | — | −81.19% |
| Q2 2015 | 2015-06-30 | −$276,522 | $433,566 | — | −1379.85% |
| Q1 2015 | 2015-03-31 | −$503,487 | $498,023 | — | −1333.39% |
| Q4 2014 | 2014-12-31 | −$470,285 | −$7,746 | — | — |
| Q3 2014 | 2014-09-30 | −$550,186 | $179,479 | — | −1045.56% |
| Q2 2014 | 2014-06-30 | −$710,088 | $64,902 | — | −629.32% |
| Q1 2014 | 2014-03-31 | −$1.0M | −$402,261 | — | −4900.95% |
| Q4 2013 | 2013-12-31 | −$462,539 | $437,983 | — | −659.92% |
| Q3 2013 | 2013-09-30 | −$729,665 | — | — | −579.51% |
| Q2 2013 | 2013-06-30 | −$774,990 | — | — | −796.66% |
| Q1 2013 | 2013-03-31 | −$599,249 | — | — | −3121.09% |
| Q3 2012 | 2012-09-30 | −$900,522 | — | — | −1835.63% |
Processa Pharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$873,305 to −$11.2M, a net decrease of $10.4M. Processa Pharmaceuticals's latest reported quarter, Q2 2017, generated −$297,230 in free cash flow, a decrease of $20,708 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Processa Pharmaceuticals filings at SEC.gov ↗